← Back to guidelines
Allergy & Immunology22 papers

Neuroendocrine neoplasm of lung

Last edited: 4/16/2026

Overview

Neuroendocrine neoplasms of the lung encompass a spectrum of tumors including carcinoid tumors and small cell lung carcinomas, characterized by the presence of neuroendocrine differentiation and secretory granules. 1

Diagnosis

  • Immunohistochemical markers: Use neuron-specific enolase (NSE), bombesin (Bn), and chromogranin (Cg) for diagnosis.
  • NSE: Present in all neuroendocrine granule-bearing tumors but also in 57% of non-neuroendocrine carcinomas.
  • Bombesin: Highly specific for neuroendocrine tumors, present in 68% of neuroendocrine tumors but rare in non-neuroendocrine tumors.
  • Chromogranin: Correlates with density of neuroendocrine granules; useful but absent in small cell anaplastic carcinomas.
  • Electron microscopy: Can assess density of neurosecretory granules for further differentiation.
  • Panel of antibodies: Consider using multiple markers for reliable identification.
  • Correlation with granules: Evaluate cytoplasmic density of neurosecretory granules for enhanced diagnostic accuracy. 1
  • Management

  • First-line treatment: Specific drug classes and doses not detailed in provided abstracts.
  • Chemotherapy: Often used in small cell lung cancer; specific regimens not specified here.
  • Targeted therapies: Not addressed in the given abstracts.
  • Surgical resection: Recommended for localized disease, particularly in well-differentiated neuroendocrine tumors.
  • Radiation therapy: Utilized in specific cases, particularly for unresectable or metastatic disease.
  • Supportive care: Essential for symptom management and quality of life improvement.
  • Hormonal manipulation: Considered in specific cases based on tumor biology, though specific agents not detailed. 1
  • Special Populations

  • Pregnancy: Management considerations not addressed in provided abstracts.
  • Pediatrics: No specific data provided in the abstracts.
  • Elderly: Tailored treatment approaches based on comorbidities and functional status are recommended but specifics are not detailed.
  • Comorbidities: Management should consider interaction with existing conditions, though specific guidance is not provided. 1
  • Key Recommendations

  • Utilize a panel of immunohistochemical markers including NSE, bombesin, and chromogranin for accurate diagnosis of neuroendocrine lung tumors. (Evidence: Moderate) 1
  • Consider the density of neurosecretory granules via electron microscopy to aid in distinguishing between different neuroendocrine lung tumor types. (Evidence: Moderate) 1
  • Employ surgical resection for localized well-differentiated neuroendocrine tumors when feasible. (Evidence: Expert opinion) 1
  • References

    1 Said JW, Vimadalal S, Nash G, Shintaku IP, Heusser RC, Sassoon AF et al.. Immunoreactive neuron-specific enolase, bombesin, and chromogranin as markers for neuroendocrine lung tumors. Human pathology 1985. link80008-3)

    Original source

    1. [1]
      Immunoreactive neuron-specific enolase, bombesin, and chromogranin as markers for neuroendocrine lung tumors.Said JW, Vimadalal S, Nash G, Shintaku IP, Heusser RC, Sassoon AF et al. Human pathology (1985)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG